- Email: [email protected]
2738 Comparing Postoperative Pain with Laparoscopic Versus Robotic Sacrocolpopexy
S208
Abstracts / Journal of Minimally Invasive Gynecology 26 (2019) S98−S231
Setting: Academic hospital. Patients or Participants: 127 women undergoing posterior colporrhaphy and/or perineorrhaphy were screened, and 72 were enrolled and included in the final analysis: 37 (51.4%) randomized to liposomal bupivacaine and 35 (48.6%) to placebo. Interventions: Liposomal bupivacaine or normal saline placebo was injected into the posterior vaginal compartment and perineal body using a systematic technique. Measurements and Main Results: The primary outcome was vaginal pain as measured by a visual analog scale (VAS). Participants completed twice daily pain and medication diaries starting on postoperative day 0 until the evening of postoperative day 3. Surgical and demographic characteristics were similar. Median VAS was not statistically different at any time point (p=0.81). Median NRS recorded in PACU were lower for the intervention group (0.0 [IQR 2.0] vs 1.5 [IQR 4.0], p=0.05). There were no differences seen in any other secondary outcomes. There were no differences in narcotic use (37.5 vs 37.5 mme, p=0.51), time to first opioid administration (89.5 vs 68.0 minutes, p=0.56), number of antiemetic doses required (2.0 vs 3.0, p=0.07), median hospital length of stay (21.9 vs 24.0 hours, p=0.98), median length of stay in PACU (100 vs 93 minutes, p=0.32), proportion of patients who had a bowel movement within first 3 postoperative days (59.5 vs 65.7% p=0.36) or who passed their voiding trial prior to hospital discharge (59.5 vs 45.7%, p=0.24). There were no differences in patient satisfaction or in adverse events. Conclusion: In this study of pelvic reconstructive surgeries with posterior colporrhaphy and/or perineorrhaphy, there were no differences in pain scores, nor any secondary outcomes, between liposomal bupivacaine and placebo injected into the posterior vaginal compartment.
Conclusion: Vaginal CO2 laser was found a safe non-invasive treatment for patients with urodynamic proven stress incontinence. Significant subjective improvement was time dependent and 68.9% reported improvement at 12-month follow-up. The objective urodynamic cure was 38.7%. The short-term efficacy is promising, however, long term follow-up and optimizing treatment protocol are needed.
Virtual Poster Session 4: Urogynecology (1:00 PM — 1:10 PM) 1:00 PM: STATION P 2110 Vaginal CO2 Laser as Minimal Non-Invasive Treatment for Urinary Stresss Incontinence Alcalay M,1,2,* Greenshpun A,2 Ben Ami M,2 Schiff E1. 1Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat Gan, Israel; 2Obstetrics and Gynecology, Pade Poria Medical Center, Tiberias, Israel *Corresponding author. Study Objective: To assess the efficacy of vaginal CO2 laser in women with urodynamic stress incontinence (USI) that were followed for one year. Design: Prospective multicenter study. Following laser treatments, the patients were followed for 3, 6 and 12 months. Setting: University affiliated hospitals Patients or Participants: Patients with USI that were graded as mild or moderate were allowed to participate. We recruited 32 patients with USI, of whom 29 completed follow-up for 12 months. Interventions: Every patient had three sessions of CO2 laser, 4-5 weeks apart. Measurements and Main Results: We used 1-hour pad test (ICS protocol), stress test, questionnaires (PFDI-20, PFIQ, Patient Global Impression of Improvement (PGI-I)) and a 3-day urinary diary at each follow-up visit. Second urodynamic test was performed at 6 months follow-up. No serious adverse events were recorded. Minor side effects that were related to treatment included: transient vaginal secretion (4 patients), vaginal irritation (1 patients), transient fever (1 patient), and UTI (1 patient). The patients’ 1 hour pad test showed significant decrease from 2 months FU and onward. Pad test and PGI-I showed time - dependency. 68.9% (20 of 29) of the patients felt improvement (PGI-I) at 12 month following the treatment, of whom 11 (37.9%) described it as “very significant” or “significant” and 9 (31%) “some” improvement. Patient’s bladder symptoms (PFDI) improved significantly between 1 to 6 months and accordingly quality of life (PFIQ) improved significantly. At 6 months - stress test with full bladder was negative in 68%, however, urodynamic assessment was negative for stress incontinence only in 38.7%.
Virtual Poster Session 4: Urogynecology (1:00 PM — 1:10 PM) 1:00 PM: STATION Q 2578 Promising Effect of Platelet-Rich Plasma And CO2 Laser in Urinary Incontinance Behnia-Willison F,1 Nguyen TTT,2,* Carey RJ,1 Lam AM3. 1Flinders Endogynaecology, Flinders Medical Centre, Adelaide, SA, Australia; 2 FBW Gynaecology Plus, Adelaide, SA, Australia; 3Centre for Advanced Reproductive Endosurgery, Sydney, NSW, Australia *Corresponding author. Study Objective: To evaluate the safety, feasibility and efficacy of transvaginal fractional micro-ablative CO2 laser therapy in combination with platelet rich plasma (PRP) for the treatment of urinary urge incontinence in women. Design: Prospective observational cohort study. Setting: Single private gynecology practice in Adelaide, Australia between 2013 and 2018. Patients or Participants: 128 women, of whom 62 women were diagnosed with stress urinary incontinence and 66 women with urinary urge incontinence. Interventions: PRP and CO2 laser were used for 3 treatments. There was 4-6 weeks interval between each treatment. Measurements and Main Results: Patient outcomes were reviewed subjectively and objectively at baseline, 3 months and 12 months. The Australian Pelvic Floor Questionnaire (APFQ) and physical examination were employed to assess outcomes. Patients with moderate to severe stress incontinence improved 63% at 12 months (p=0.001) Patients with moderate to severe urge incontinence improved 55% at 12 months (p=0.003) Conclusion: PRP and vaginal laser appear to be promising alternative treatments for urinary incontinence with potential reduction in cost to both the patient and national health systems without any complications or sideeffects. However, the true efficacy of these modalities need to be examined in an RCT setting. Virtual Poster Session 4: Urogynecology (1:00 PM — 1:10 PM) 1:00 PM: STATION R 2738 Comparing Postoperative Pain with Laparoscopic Versus Robotic Sacrocolpopexy Schmidt MF,1,2,* Turner L,3 Bradley M,4 Shepherd J2. 1Department of Obstetrics and Gynecology, UConn Health, Farmington, CT; 2Department of Obstetrics/Gynecology, Trinity Health of New England, Hartford, CT; 3 Division of Urogynecology, Allegheny Health Network, Pittsburgh, PA; 4 Division of Urogynecology and Pelvic Reconstructive Surgery, University of Pittsburgh, Magee-Womens Research Institute, Pittsburgh, PA *Corresponding author. Study Objective: To compare postoperative pain and pain-related outcomes following laparoscopic (LS-MISC) versus robotic minimally invasive sacrocolpopexy (R-MISC). Design: Secondary analysis of placebo-controlled RCT examining preoperative IV acetaminophen on postoperative pain following MISC. Setting: Planned secondary analysis of multicenter RCT.
Abstracts / Journal of Minimally Invasive Gynecology 26 (2019) S98−S231
S209
Patients or Participants: Women undergoing MISC. Interventions: Primary outcome was total narcotics within 24 hours in morphine mg equivalents (MME) comparing LS-MISC and R-MISC. Measurements and Main Results: We included 90 subjects undergoing MISC: 65 LS-MISC and 25 R-MISC. Most were Caucasian (97.8%) and postmenopausal (88.9%) with mean age 61.2§7.2 years and BMI 27.6§ 4.4 kg/m2. IV acetaminophen did not impact pain in the original study and was similar between LS-MISC and R-MISC. Baseline POP-Q stage was similar between groups. Concomitant hysterectomy was performed in 67% with LS-MISC, 60% with R-MISC (p=0.49). LS-MISC underwent more concomitant perineorrhaphies (15.4% vs 0%, p=0.04) and posterior repairs (18.5% vs 0%, p=0.02). Operative time was longer with LSMISC (208.5§57.3 vs 143.6§21.0 minutes, p=<0.001). Length of stay was also longer with LS-MISC (0.9§0.4 vs 0.7§0.4 days, p=0.02). Women undergoing LS-MISC consumed more narcotics in the first 24 hours when including intraoperative narcotics (48.5§25.5 vs 35.1§ 14.6 MME, p=0003). Using linear regression correcting for operative time and concomitant vaginal repairs, this difference disappeared. Likewise, when intraoperative narcotics were excluded, there was no difference. APS-POQ-R side effect questionnaire (0-10 points) only showed increased drowsiness with LS-MISC (4.4§3.3 vs 2.8§2.6, p=0.045). PROMIS scores (pain’s impact on quality of life) were similar. There were no differences in 24 hour post-operative VAS scores, narcotic use in first week after surgery, nausea, urinary retention, or return of bowel function. Conclusion: L-MISC showed increased length of stay and drowsiness. Most other outcomes showed either no difference or differences disappeared once adjusting for confounders as with primary outcome. Overall, MME narcotic use and VAS pain scales were low as were narcotic medication side effects.
required treatment by tape removal or catheterization. However, 16 patients (16/73, 21.9%) had voiding changes compared with their preoperative status. Persistent groin pain was reported in 1.4% of the patients, and tape exposure occurred in 5.5%. The subjective satisfaction rate and objective cure rate were 80.8% and 82.2%, respectively. Compared with preoperative scores, the IIQ-7 score decreased significantly (P < 0.05), whilst there was no significant difference in the PISQ-12 score (P =0.893). Conclusion: This 12-year follow-up study showed that TVT-O is a highly effective procedure for the treatment of SUI. The long-term complication rate appears to be slightly high, which should raise concern.
Virtual Poster Session 4: Urogynecology (1:00 PM — 1:10 PM) 1:00 PM: STATION S 1296 Tension-free Vaginal Tape-obturator for the Treatment of Stress Urinary Incontinence: A 12-Year Prospective Follow-Up Zhu L,* Zhang Y. Department of Gynecology and Obstetrics, Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China *Corresponding author. Study Objective: To evaluate the long-term safety and effectiveness of inside−out transobturator tape (tension-free vaginal tape-obturator, TVTO) for the treatment of stress urinary incontinence (SUI). Design: A prospective cohort study. The duration of follow-up was 12years. Setting: Center of obstetrics and gynecology in a tertiary-care hospital. Patients or Participants: Between August 2004 and August 2006, 87 consecutive patients with SUI who underwent TVT-O were enrolled in this prospective cohort study. Patients with mixed UI, or pelvic organ prolapse requiring surgery, were excluded. Interventions: TVT-O procedures were performed for each patients enrolled. Measurements and Main Results: Data relating to long-term postoperative complications, subjective satisfaction rate (Patient Global Impression of Improvement), objective cure rate (stress test), quality of life (QoL), and sexual function, were collected during follow-up. The Incontinence Impact Questionnaire (IIQ-7) and Pelvic Organ Prolapse/ Urinary Incontinence Sexual Questionnaire (PISQ-12) were used to assess QoL and sexual function, respectively. Statistical analyses were performed using paired-sample t-tests. At the 12-year follow-up, 73 patients (84%) were available for evaluation. Overall, the long-term complication rate was 45.2%. De novo overactive bladder was observed in 12.3% of patients. None of the patients reported severe voiding dysfunction that
Virtual Poster Session 4: Urogynecology (1:00 PM — 1:10 PM) 1:00 PM: STATION T 1295 A National Population-Based Survey of the Prevalence, Potential Risk Factors, and SymptomSpecific Bother in Symptomatic Pelvic Organ Prolapse in Adult Chinese Women−Pelvic Organ Prolapse Quantification System Based Study Zhu L,* Zhang L. Department of Gynecology and Obstetrics, Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China *Corresponding author. Study Objective: To provide estimates of the prevalence and potential risk factors associated with pelvic organ prolapse (POP) based on Pelvic Organ Prolapse quantification (POP-Q) system and the bother it imposes in a nationwide population-based sample of adult women in China. Design: A national cross-sectional study from February 2014 through March 2016. Setting: Mainland China. Patients or Participants: A nationally representative sample of 54,000 adults who were 20 years old or older were sampled using multi-stage, stratified, cluster sampling at six populous provinces in mainland China among participants of National Mass Screening on Breast and Cervical Cancers. Interventions: No interventions were conducted. Measurements and Main Results: POP was assessed using POP-Q stage and validation questionnaires. Multivariable logistic regression was used to assess factors associated with each degree or bother POP. The prevalence of symptomatic POP (POP-Q stage II or higher) was 9.56%. Stage II POP was the most common (7.52%) and mainly involved anterior compartment. Incidence increased with age for all stages (P≤0.05). Minor or moderate bother were the most common responses that were reported for every stage of POP (9.72%). Only 0.08% of the participants reported that the condition had a severe impact on their quality of life. Older age, postmenopausal status, and multiple vaginal deliveries increased the odds of every kind of POP (p ≤ 0.05). Conclusion: Based on physical objective examination, our study yielded a Lower prevalence than that in other surveys and mainly involved anterior compartment, which suggests that it should be considered for medical intervention. Older age, postmenopausal status, and multiple vaginal deliveries increased the odds of every kind of POP. Virtual Poster Session 4: Urogynecology (1:10 PM — 1:20 PM) 1:10 PM: STATION A 1344 The Modern Office Exam of the Mature Woman Sosa-Stanley JN,1,* Boulden NK,2 Lucente VR3. 1Minimally Invasive Gynecologic Surgery, St. Luke’s University Health Network, Allentown, PA; 2OB/GYN, St. Luke’s University Health Network, Allentown, PA; 3 Urogynecology, The Institute for Female Pelvic Medicine, Allentown, PA *Corresponding author.
Abstracts / Journal of Minimally Invasive Gynecology 26 (2019) S98−S231
Setting: Academic hospital. Patients or Participants: 127 women undergoing posterior colporrhaphy and/or perineorrhaphy were screened, and 72 were enrolled and included in the final analysis: 37 (51.4%) randomized to liposomal bupivacaine and 35 (48.6%) to placebo. Interventions: Liposomal bupivacaine or normal saline placebo was injected into the posterior vaginal compartment and perineal body using a systematic technique. Measurements and Main Results: The primary outcome was vaginal pain as measured by a visual analog scale (VAS). Participants completed twice daily pain and medication diaries starting on postoperative day 0 until the evening of postoperative day 3. Surgical and demographic characteristics were similar. Median VAS was not statistically different at any time point (p=0.81). Median NRS recorded in PACU were lower for the intervention group (0.0 [IQR 2.0] vs 1.5 [IQR 4.0], p=0.05). There were no differences seen in any other secondary outcomes. There were no differences in narcotic use (37.5 vs 37.5 mme, p=0.51), time to first opioid administration (89.5 vs 68.0 minutes, p=0.56), number of antiemetic doses required (2.0 vs 3.0, p=0.07), median hospital length of stay (21.9 vs 24.0 hours, p=0.98), median length of stay in PACU (100 vs 93 minutes, p=0.32), proportion of patients who had a bowel movement within first 3 postoperative days (59.5 vs 65.7% p=0.36) or who passed their voiding trial prior to hospital discharge (59.5 vs 45.7%, p=0.24). There were no differences in patient satisfaction or in adverse events. Conclusion: In this study of pelvic reconstructive surgeries with posterior colporrhaphy and/or perineorrhaphy, there were no differences in pain scores, nor any secondary outcomes, between liposomal bupivacaine and placebo injected into the posterior vaginal compartment.
Conclusion: Vaginal CO2 laser was found a safe non-invasive treatment for patients with urodynamic proven stress incontinence. Significant subjective improvement was time dependent and 68.9% reported improvement at 12-month follow-up. The objective urodynamic cure was 38.7%. The short-term efficacy is promising, however, long term follow-up and optimizing treatment protocol are needed.
Virtual Poster Session 4: Urogynecology (1:00 PM — 1:10 PM) 1:00 PM: STATION P 2110 Vaginal CO2 Laser as Minimal Non-Invasive Treatment for Urinary Stresss Incontinence Alcalay M,1,2,* Greenshpun A,2 Ben Ami M,2 Schiff E1. 1Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat Gan, Israel; 2Obstetrics and Gynecology, Pade Poria Medical Center, Tiberias, Israel *Corresponding author. Study Objective: To assess the efficacy of vaginal CO2 laser in women with urodynamic stress incontinence (USI) that were followed for one year. Design: Prospective multicenter study. Following laser treatments, the patients were followed for 3, 6 and 12 months. Setting: University affiliated hospitals Patients or Participants: Patients with USI that were graded as mild or moderate were allowed to participate. We recruited 32 patients with USI, of whom 29 completed follow-up for 12 months. Interventions: Every patient had three sessions of CO2 laser, 4-5 weeks apart. Measurements and Main Results: We used 1-hour pad test (ICS protocol), stress test, questionnaires (PFDI-20, PFIQ, Patient Global Impression of Improvement (PGI-I)) and a 3-day urinary diary at each follow-up visit. Second urodynamic test was performed at 6 months follow-up. No serious adverse events were recorded. Minor side effects that were related to treatment included: transient vaginal secretion (4 patients), vaginal irritation (1 patients), transient fever (1 patient), and UTI (1 patient). The patients’ 1 hour pad test showed significant decrease from 2 months FU and onward. Pad test and PGI-I showed time - dependency. 68.9% (20 of 29) of the patients felt improvement (PGI-I) at 12 month following the treatment, of whom 11 (37.9%) described it as “very significant” or “significant” and 9 (31%) “some” improvement. Patient’s bladder symptoms (PFDI) improved significantly between 1 to 6 months and accordingly quality of life (PFIQ) improved significantly. At 6 months - stress test with full bladder was negative in 68%, however, urodynamic assessment was negative for stress incontinence only in 38.7%.
Virtual Poster Session 4: Urogynecology (1:00 PM — 1:10 PM) 1:00 PM: STATION Q 2578 Promising Effect of Platelet-Rich Plasma And CO2 Laser in Urinary Incontinance Behnia-Willison F,1 Nguyen TTT,2,* Carey RJ,1 Lam AM3. 1Flinders Endogynaecology, Flinders Medical Centre, Adelaide, SA, Australia; 2 FBW Gynaecology Plus, Adelaide, SA, Australia; 3Centre for Advanced Reproductive Endosurgery, Sydney, NSW, Australia *Corresponding author. Study Objective: To evaluate the safety, feasibility and efficacy of transvaginal fractional micro-ablative CO2 laser therapy in combination with platelet rich plasma (PRP) for the treatment of urinary urge incontinence in women. Design: Prospective observational cohort study. Setting: Single private gynecology practice in Adelaide, Australia between 2013 and 2018. Patients or Participants: 128 women, of whom 62 women were diagnosed with stress urinary incontinence and 66 women with urinary urge incontinence. Interventions: PRP and CO2 laser were used for 3 treatments. There was 4-6 weeks interval between each treatment. Measurements and Main Results: Patient outcomes were reviewed subjectively and objectively at baseline, 3 months and 12 months. The Australian Pelvic Floor Questionnaire (APFQ) and physical examination were employed to assess outcomes. Patients with moderate to severe stress incontinence improved 63% at 12 months (p=0.001) Patients with moderate to severe urge incontinence improved 55% at 12 months (p=0.003) Conclusion: PRP and vaginal laser appear to be promising alternative treatments for urinary incontinence with potential reduction in cost to both the patient and national health systems without any complications or sideeffects. However, the true efficacy of these modalities need to be examined in an RCT setting. Virtual Poster Session 4: Urogynecology (1:00 PM — 1:10 PM) 1:00 PM: STATION R 2738 Comparing Postoperative Pain with Laparoscopic Versus Robotic Sacrocolpopexy Schmidt MF,1,2,* Turner L,3 Bradley M,4 Shepherd J2. 1Department of Obstetrics and Gynecology, UConn Health, Farmington, CT; 2Department of Obstetrics/Gynecology, Trinity Health of New England, Hartford, CT; 3 Division of Urogynecology, Allegheny Health Network, Pittsburgh, PA; 4 Division of Urogynecology and Pelvic Reconstructive Surgery, University of Pittsburgh, Magee-Womens Research Institute, Pittsburgh, PA *Corresponding author. Study Objective: To compare postoperative pain and pain-related outcomes following laparoscopic (LS-MISC) versus robotic minimally invasive sacrocolpopexy (R-MISC). Design: Secondary analysis of placebo-controlled RCT examining preoperative IV acetaminophen on postoperative pain following MISC. Setting: Planned secondary analysis of multicenter RCT.
Abstracts / Journal of Minimally Invasive Gynecology 26 (2019) S98−S231
S209
Patients or Participants: Women undergoing MISC. Interventions: Primary outcome was total narcotics within 24 hours in morphine mg equivalents (MME) comparing LS-MISC and R-MISC. Measurements and Main Results: We included 90 subjects undergoing MISC: 65 LS-MISC and 25 R-MISC. Most were Caucasian (97.8%) and postmenopausal (88.9%) with mean age 61.2§7.2 years and BMI 27.6§ 4.4 kg/m2. IV acetaminophen did not impact pain in the original study and was similar between LS-MISC and R-MISC. Baseline POP-Q stage was similar between groups. Concomitant hysterectomy was performed in 67% with LS-MISC, 60% with R-MISC (p=0.49). LS-MISC underwent more concomitant perineorrhaphies (15.4% vs 0%, p=0.04) and posterior repairs (18.5% vs 0%, p=0.02). Operative time was longer with LSMISC (208.5§57.3 vs 143.6§21.0 minutes, p=<0.001). Length of stay was also longer with LS-MISC (0.9§0.4 vs 0.7§0.4 days, p=0.02). Women undergoing LS-MISC consumed more narcotics in the first 24 hours when including intraoperative narcotics (48.5§25.5 vs 35.1§ 14.6 MME, p=0003). Using linear regression correcting for operative time and concomitant vaginal repairs, this difference disappeared. Likewise, when intraoperative narcotics were excluded, there was no difference. APS-POQ-R side effect questionnaire (0-10 points) only showed increased drowsiness with LS-MISC (4.4§3.3 vs 2.8§2.6, p=0.045). PROMIS scores (pain’s impact on quality of life) were similar. There were no differences in 24 hour post-operative VAS scores, narcotic use in first week after surgery, nausea, urinary retention, or return of bowel function. Conclusion: L-MISC showed increased length of stay and drowsiness. Most other outcomes showed either no difference or differences disappeared once adjusting for confounders as with primary outcome. Overall, MME narcotic use and VAS pain scales were low as were narcotic medication side effects.
required treatment by tape removal or catheterization. However, 16 patients (16/73, 21.9%) had voiding changes compared with their preoperative status. Persistent groin pain was reported in 1.4% of the patients, and tape exposure occurred in 5.5%. The subjective satisfaction rate and objective cure rate were 80.8% and 82.2%, respectively. Compared with preoperative scores, the IIQ-7 score decreased significantly (P < 0.05), whilst there was no significant difference in the PISQ-12 score (P =0.893). Conclusion: This 12-year follow-up study showed that TVT-O is a highly effective procedure for the treatment of SUI. The long-term complication rate appears to be slightly high, which should raise concern.
Virtual Poster Session 4: Urogynecology (1:00 PM — 1:10 PM) 1:00 PM: STATION S 1296 Tension-free Vaginal Tape-obturator for the Treatment of Stress Urinary Incontinence: A 12-Year Prospective Follow-Up Zhu L,* Zhang Y. Department of Gynecology and Obstetrics, Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China *Corresponding author. Study Objective: To evaluate the long-term safety and effectiveness of inside−out transobturator tape (tension-free vaginal tape-obturator, TVTO) for the treatment of stress urinary incontinence (SUI). Design: A prospective cohort study. The duration of follow-up was 12years. Setting: Center of obstetrics and gynecology in a tertiary-care hospital. Patients or Participants: Between August 2004 and August 2006, 87 consecutive patients with SUI who underwent TVT-O were enrolled in this prospective cohort study. Patients with mixed UI, or pelvic organ prolapse requiring surgery, were excluded. Interventions: TVT-O procedures were performed for each patients enrolled. Measurements and Main Results: Data relating to long-term postoperative complications, subjective satisfaction rate (Patient Global Impression of Improvement), objective cure rate (stress test), quality of life (QoL), and sexual function, were collected during follow-up. The Incontinence Impact Questionnaire (IIQ-7) and Pelvic Organ Prolapse/ Urinary Incontinence Sexual Questionnaire (PISQ-12) were used to assess QoL and sexual function, respectively. Statistical analyses were performed using paired-sample t-tests. At the 12-year follow-up, 73 patients (84%) were available for evaluation. Overall, the long-term complication rate was 45.2%. De novo overactive bladder was observed in 12.3% of patients. None of the patients reported severe voiding dysfunction that
Virtual Poster Session 4: Urogynecology (1:00 PM — 1:10 PM) 1:00 PM: STATION T 1295 A National Population-Based Survey of the Prevalence, Potential Risk Factors, and SymptomSpecific Bother in Symptomatic Pelvic Organ Prolapse in Adult Chinese Women−Pelvic Organ Prolapse Quantification System Based Study Zhu L,* Zhang L. Department of Gynecology and Obstetrics, Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China *Corresponding author. Study Objective: To provide estimates of the prevalence and potential risk factors associated with pelvic organ prolapse (POP) based on Pelvic Organ Prolapse quantification (POP-Q) system and the bother it imposes in a nationwide population-based sample of adult women in China. Design: A national cross-sectional study from February 2014 through March 2016. Setting: Mainland China. Patients or Participants: A nationally representative sample of 54,000 adults who were 20 years old or older were sampled using multi-stage, stratified, cluster sampling at six populous provinces in mainland China among participants of National Mass Screening on Breast and Cervical Cancers. Interventions: No interventions were conducted. Measurements and Main Results: POP was assessed using POP-Q stage and validation questionnaires. Multivariable logistic regression was used to assess factors associated with each degree or bother POP. The prevalence of symptomatic POP (POP-Q stage II or higher) was 9.56%. Stage II POP was the most common (7.52%) and mainly involved anterior compartment. Incidence increased with age for all stages (P≤0.05). Minor or moderate bother were the most common responses that were reported for every stage of POP (9.72%). Only 0.08% of the participants reported that the condition had a severe impact on their quality of life. Older age, postmenopausal status, and multiple vaginal deliveries increased the odds of every kind of POP (p ≤ 0.05). Conclusion: Based on physical objective examination, our study yielded a Lower prevalence than that in other surveys and mainly involved anterior compartment, which suggests that it should be considered for medical intervention. Older age, postmenopausal status, and multiple vaginal deliveries increased the odds of every kind of POP. Virtual Poster Session 4: Urogynecology (1:10 PM — 1:20 PM) 1:10 PM: STATION A 1344 The Modern Office Exam of the Mature Woman Sosa-Stanley JN,1,* Boulden NK,2 Lucente VR3. 1Minimally Invasive Gynecologic Surgery, St. Luke’s University Health Network, Allentown, PA; 2OB/GYN, St. Luke’s University Health Network, Allentown, PA; 3 Urogynecology, The Institute for Female Pelvic Medicine, Allentown, PA *Corresponding author.